Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia

National Cancer Institute

Source


Acute myeloid leukemias arising as a result of the mutagenic effect of therapeutic agents targeting DNA-topoisomerase II. The vast majority of patients present without a preceding myelodysplastic phase. The acute myeloid leukemias are usually of the monoblastic or myelomonocytic type. Clonal cytogenetic abnormalities are frequently present and usually involve chromosome 11q23 (MLL gene).